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Background: Publicly available data show variation in GPs’ use of urgent suspected cancer (USC) referral pathways. We
investigated whether this could be due to small numbers of cancer cases and random case-mix, rather than due to true variation in
performance.
Methods: We analysed individual GP practice USC referral detection rates (proportion of the practice’s cancer cases that are
detected via USC) and conversion rates (proportion of the practice’s USC referrals that prove to be cancer) in routinely collected
data from GP practices in all of England (over 4 years) and northeast Scotland (over 7 years). We explored the effect of pooling
data. We then modelled the effects of adding random case-mix to practice variation.
Results: Correlations between practice detection rate and conversion rate became less positive when data were aggregated over
several years. Adding random case-mix to between-practice variation indicated that the median proportion of poorly performing
practices correctly identified after 25 cancer cases were examined was 20% (IQR 17 to 24) and after 100 cases was 44% (IQR 40 to 47).
Conclusions: Much apparent variation in GPs’ use of suspected cancer referral pathways can be attributed to random case-mix.
The methods currently used to assess the quality of GP-suspected cancer referral performance, and to compare individual
practices, are misleading. These should no longer be used, and more appropriate and robust methods should be developed.
Early detection and treatment of cancer is an important goal for
health services. The United Kingdom (UK) and other countries
with strong primary care ‘gatekeeper’ systems persistently display
lower cancer survival rates when compared with other developed
countries. This effect is widely attributed to longer intervals in
the cancer diagnostic and treatment pathway (Richards, 2009;
Coleman et al, 2011).
The UK NHS has existing fast-track urgent suspected cancer
(USC) referral pathways from primary to secondary care (NICE,
2005; Scottish Government, 2009). In England, patients referred
from primary care with suspected cancer should be seen in
secondary care within 2 weeks (hence the common term ‘2-week
wait referrals’; Meechan et al, 2012; Department of Health, 2000)
and begin treatment within 62 days (England and Scotland;
Department of Health 2000; Scottish Executive Health
Department, 2007).
There is evidence that practices vary in the frequency with
which they make USC referrals. In Scotland, an analysis of 18 775
USC referrals in 2008 reported a six-fold variation in the use of this
referral route (Baughan et al, 2011). Similar variation was shown in
an analysis of 865 494 referrals in England over 1 year (Meechan
et al, 2012). This latter analysis also found a positive correlation
between practices’ detection rate (the proportion of all cancers
referred as USC) and conversion rate (the proportion of all USC
referrals resulting in a cancer diagnosis; Supplementary Appendix 1).
This correlation has been used as evidence of a quality gradient:
with ‘high-quality’ practices being both more accurate (higher
detection rate) and more efficient (higher conversion rate) in their
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use of USC than others (Meechan et al, 2012). In England, the
National Cancer Intelligence Network now publishes GP practice
profiles for cancer that include annual detection and conversion
rates (National Cancer Intelligence Network, 2012). This has led to
media reports of unacceptable variations in GP performance
culminating in the recent recommendation by the UK Health
Secretary that ‘poorly performing’ practices be publicly named.
(BBC Website, 2013; BBC Website, 2014).
Current reporting is based on referral data from a single year
and does not distinguish between different cancer types. New cases
of cancer are relatively uncommon in primary care, and therefore
the number of cases in any year will be small. Furthermore, cancer
in primary care is heterogeneous: some cancers typically present
with features amenable to prompt recognition and referral
(e.g., testicular cancer presenting as a lump), whereas others
typically have nonspecific symptoms (e.g., ovarian cancer; Bottle
et al, 2012). This is reflected in substantial differences in the use of
the USC pathway according to cancer type (National Cancer
Intelligence Network, 2014). Even within the same cancer type,
some presentations will prompt urgent referral (e.g., lung cancer
presenting with haemoptysis), whereas others may not (e.g., lung
cancer presenting with nonspecific symptoms; Birring and Peake,
2005). Furthermore, presymptomatic cancers that had been
detected via national screening programmes are currently counted
in the non-USC category, introducing a further source of variation
in apparent GP performance.
Current national guidelines dictate which circumstances
warrant USC referral; thus, adherence to these will inevitably
influence which referral route GPs choose. Thus, depending on
case-mix, two practices following guidelines equally well may have
different detection and conversion rates with the appearance, based
on current metrics, that one is better than the other (Dua et al, 2009).
The aim of our study was to investigate the effect of the number
of cancer cases and random case-mix on the variation in GP
performance in cancer diagnosis and their implication for public
reporting. First, we examined the effect of aggregating data for each
practice over several years on the proposed ‘quality gradient’
indicated by the association between detection and conversion rates.
Second, we examined year-to-year correlation in detection and
conversion rates in order to assess whether practices were consistent
over time in their reported rates. Finally, we carried out a simulation
modelling study to estimate the variation in USC rates attributable
to random case-mix and used this to estimate the likelihood that a
poorly performing practice would be correctly identified.
MATERIALS AND METHODS
Data sources. The current study used two databases. The first
provided data on the route of cancer diagnosis, including USC
referral from primary care over 7 years (2006–2012) in the NHS
Grampian region of northeast Scotland. The second contained data
on the route of cancer diagnosis including 2-week referrals over
4 years (2010–2013) from NHS England. USC in Scotland and
2-week referrals in England are the broadly equivalent referral
routes by which GPs in Scotland and England, respectively, secure
an urgent secondary care appointment for patients in whom a
strong suspicion of cancer is supported by existing guidelines.
The data from northeast Scotland comprised practice-level data
for all GP practices in the NHS Grampian region relating to all
cancer diagnoses and all USC referrals made between 2 January
2006 and 30 November 2012. These were obtained from the NHS
Grampian Cancer Care Pathway database (CCPd). The CCPd is a
detailed clinical database maintained by NHS Grampian, recording
information about all cancer referrals made by GPs within the
region, as well as information about all cancer diagnoses,
irrespective of route of diagnosis. The start date for these data
represents the earliest date of collection of USC referral data. The
NHS England data comprised publicly available practice-level data
for all GP practices on the NCIN website (National Cancer
Intelligence Network, 2014) for the years 2010–2013 inclusive.
Data processing and analysis. With the NHS Grampian data, for
each practice and year, we extracted the total number of cancers,
the number of cancers detected after USC referral and the total
number of USC referrals. We also used demographic data from
each practice to calculate age–sex-standardised referral ratios based
on the number of USC referrals that would have been expected
from the practice relative to other practices in NHS Grampian.
With the NHS England data, for each practice and year, we
extracted the total number of cancers treated, the number of
cancers detected after USC referral and the total number of USC
referrals. We also extracted the age–sex-standardised referral rate.
With both extracted data sets, we calculated the detection and
conversion rates for each practice for each year and aggregated
across years. These are analogous to the sensitivity and positive
predictive value, respectively, of a diagnostic test: in this case, the
‘diagnostic test’ is the practice GPs’ decision to refer patients via
the USC route. We used these measures because they have been
promoted for comparison between practices and are currently
being made publicly available (Meechan et al, 2012; National
Cancer Intelligence Network, 2014).
In both databases, we found that some practices had only a
small number of cancer cases. For the NHS Grampian data set,
data from practice-years that contained no cancers diagnosed via
the USC pathway were included in the analysis of aggregated
practice data but excluded from investigation of detection and
conversion rates. In the NHS England data, where there were less
than six cancers referred or diagnosed in a year for a practice, the
exact number was not published; thus, the corresponding record
from that year was excluded from all analyses.
For each individual practice-year and for practice data
aggregated across all years, we plotted detection and conversion
rates as scatter plots, with lines fitted by linear and local
polynomial regression, and calculated the correlation coefficient
between detection and conversion rates. This followed the method
previously used on single-year data (Meechan et al, 2012) and used
the Spearman rank correlation coefficient with bootstrapped
confidence interval (CI) method for both data sets. We calculated
the mean and standard deviation of the detection and conversion
rates for aggregate data from all practices and by three different
case volumes of cancer diagnosis over the study periods (1–75,
76–150 and 151–400 cases).
Year to year correlation. We calculated the year-to-year correlation
of practice detection and conversion rates, using the Spearman rank
correlation coefficient, for all pairs of adjacent years. To examine the
effects of number of cancers on these correlations, we analysed this
by subgroups of practices according to the number of new cancer
cases in 1 year.
Simulation modelling. In order to examine the effect of random
case-mix at practices of different sizes, we generated sets of
simulated GP ‘practices’. Within each set, we introduced three
sources of variation in measured performance: true practice
variation, random case-mix and practice case numbers.
These were introduced as follows:
True practice variation. This represents the between-practice
variation in performance, such as would result from differences in
competence, population or organisation. It was introduced by
randomly allocating each practice its own practice detection rate,
taken from a normal distribution with the mean set at the overall
mean detection rate from the NCIN data (0.477). The standard
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deviation for this distribution was set to one of three arbitrary
values chosen to represent low, moderate and high true practice
variation (0.025, 0.05 and 0.075, respectively).
Practice case numbers. This was introduced to examine the effect
of different numbers of cancer cases on reported variation. We set
practice case numbers at values of 25, 50, 75, 100, 150 and 200
cases. For reference, an average-sized practice withB6000 patients
can expect around 25 new cancers in a year.
Random case-mix. This represents the within-practice variation in
performance resulting from the characteristics of individual cancer
cases. It assumes that the difficulty in diagnosis lies in each case,
such that two equally performing doctors, following guidelines,
would vary in observed performance according to the cases they
saw. It was introduced by having practices randomly sample their
specified number of ‘cases’ from a larger pool of cases. Cases in this
larger pool were all allocated a ‘referral route’ property in advance
(either USC or other), with the proportion of USC cases set at the
practice detection rate. As a result, the observed detection rate for
each ‘practice’ represented a single sampling from a binomial
distribution whose probability parameter was sampled from
a Gaussian distribution.
Modelling procedure. We created 18 model specifications (three
levels of between-practice variation  six practice case numbers).
Each specification of the model was constructed for sets of 1000
practices and run 200 times. Within each specification, we
recorded the minimum, maximum, mean and standard deviation
of the detection rate within each run. We then summarised them
by calculating the medians of these measures over all runs.
Within each specification, we designated ‘practices’ whose
practice detection rate was in the lowest decile of the distribution
as poorly performing. After adding the effects of random case-mix,
we recorded the number of these that were correctly identified as
poorly performing (still in the lowest decile of the distribution). We
also recorded the number of practices that were incorrectly
identified as poorly performing (i.e., practice detection rate outside
the lowest decile before introducing the case-mix, but in the lowest
decile afterwards). For both of these measures, we reported the
median and interquartile range across all of the runs for each
model specification.
Comparison with published data. We compared the standard
deviation seen in each of the model specifications with the data
from both NHS Grampian and NHS England for comparable
cancer case numbers (expressed as a range either side of the model
specification number). Statistical analyses and modelling were
conducted using SPSS for Windows Version 20 (IBM Corp,
Armonk, NY, USA) and R version 3.02.
RESULTS
NHS Grampian data included 25 278 USC referrals and 10 615
cancers from 77 practices over a 7-year period. When practice-
years with no cancers diagnosed via the USC pathway in the NHS
Grampian data set were excluded, there were 24 934 USC referrals
and 9945 cancers. NHS England data included 4 158 358 USC
referrals and 955 502 cancers from 8303 practices over a 4-year
period. When incomplete data (from practice-years with less than
six recorded cancer cases referred by USC) were excluded from the
NHS England data, there were 3 808 406 USC referrals and 881 078
cancers remaining from 6735 practices. Characteristics of the
included practices are shown in Table 1. The NHS Grampian data
set included a higher proportion of very small practices (list size
o3000) than in England (20.8% vs 9.3%). The mean and standard
deviation practice detection and conversion rates for data
aggregated over 7 years in the NHS Grampian were 0.38 (0.10)
and 0.18 (0.06), respectively; for NHS England over 4 years, they
were 0.48 (0.09) and 0.12 (0.06).
Table 2 shows that, overall, 4003 (37.7%) cancers in the NHS
Grampian data set were referred by the USC pathway. The
detection rate was particularly low in 2006–2008; this finding
appears to reflect unfamiliarity with implementation of the USC
referral system as more than half of cancers diagnosed after urgent
referral went through generic urgent pathways as opposed to
cancer-specific ones (data available on request). From 2009
onwards, 3435 out of 6639 (51.6%) cancers in the NHS Grampian
were referred by the USC pathway. In the NHS England data set,
413 718 out of 881 080 (47.0%) cancers were referred by the USC
pathway.
Correlation coefficients between practice detection and conversion
rates for individual years ranged from 0.08 (95% CI  0.25 to 0.35)
to 0.28 (0.08 to 0.53) in NHS Grampian and between 0.24
(0.21 to 0.26) and 0.26 (0.23 to 0.28) in NHS England, as shown in
Table 3. When practice data over several years were aggregated, the
correlation was weakened in both data sets: 2006–2012 in
NHS Grampian  0.22 ( 0.41 to 0.08) and in NHS England
0.12 (0.09 to 0.14). Limiting the NHS Grampian data to cancers
diagnosed from 2009 onwards had little effect on the pooled
correlation:  0.16 ( 0.34 to 0.01). The relationship between
detection and conversion rates is shown graphically in Figure 1 for
years common to both data sets and for aggregated data. However,
the positive correlations between detection and conversion rates in
individual years may be spurious. Both detection and conversion
rates feature the number of cancers diagnosed via the USC
pathway as both the numerator and part of the denominator.
Consequently, in a practice-year with a high proportion of
‘clinically obvious’ cancers, that is, clinical presentations that
clearly meet criteria for USC referral, both detection and
conversion rates will be relatively high. Conversely, when the
proportion of clinically obvious cancers is low, both detection and
conversion rates will be low. This may lead to a spurious
correlation between the detection and conversion rates, which is
more likely to occur with small sample sizes and/or substantial
Table 1. Practice, detection and referral characteristics of the
two databases
Northeast Scotland NHS England
Number % Number %
Practice list size (N¼77) (N¼6735)
o3000 16 20.8 628 9.3
3001–6000 16 20.8 2121 31.5
6001–12000 34 44.2 3079 45.7
412000 11 14.3 907 13.5
Age-standardised annual referral ratioa
o0.8 30 39.0 1936 28.7
0.8–1.0 30 39.0 3113 46.2
41.2 17 22.1 1686 25.0
Overall ratesb Mean s.d.c Mean s.d.
Detection rate 0.382 0.098 0.477 0.085
Conversion rate 0.178 0.058 0.124 0.057
Detection rate by number of cases
25–75 cases 0.361 0.087 0.485 0.085
76–150 cases 0.353 0.072 0.464 0.073
151–400 cases 0.389 0.057 0.468 0.064
aThe indirectly standardised number of referrals via the urgent suspected cancer pathway
relative to a practice’s size and age and sex composition.
bRates for NHS Grampian data include all 7 years (2006–2012).
cStandard deviation.
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case-mix. When numbers of cancers are pooled, this spurious
correlation will be diminished.
In the NHS England data, there was a clear difference between
detection and conversion rates in their year-to-year correlations.
For practice detection rates, practice pooled correlations between
pairs of consecutive years were weak, between 0.20 (95% CI 0.17 to
0.22) and 0.26 (0.23 to 0.29), suggesting practice detection rates
were not consistent from year to year. In contrast, year-to-year
correlations for practice pooled conversion rate were moderately
strong, between 0.53 (0.51 to 0.55) and 0.55 (0.53 to 0.57),
suggesting greater consistency from year to year. Table 4 shows the
results of this analysis with practices subgrouped according to their
number of cases. Similar year-to-year analysis on NHS Grampian
data was limited by quite small numbers after excluding practices
with no cancers in one or the other year, and thus CIs were wide
(Table 4).
The simulation modelling of detection rates is reported in Table 5.
The first column indicates whether the model specification included
low, medium or high between-practice variation. The observed
standard deviation values in the second column are consistently larger
than the standard deviation values used to simulate true practice
variation, indicating that case-mix increases the observed variance.
Unsurprisingly, this difference is greater when the number of cases is
small. The implications of this increase in variance due to case-mix
are shown in the columns of Table 5 relating to ‘poor performing
practices’. The first pair shows the number of practices in the
simulations (median with interquartile range) that were specified as
poorly performing before the addition of case-mix and were
subsequently detected after the introduction of case-mix variation.
The second pair of columns shows the total number of practices
that were in the lowest decile for detection rate after introducing
random case-mix.
Comparison of the pattern of standard deviations for different
levels of between-practice variation (Table 5) with the standard
deviations for practices whose aggregate number of cancers was
low (25–75), medium (76–150) or large (151–400) from the
empirical data in Table 1 suggests that the model with moderate
between-practice variation is most closely matched to the actual
data from both empirical data sets. The implication of this is that,
with 25 cancer cases per practice, only a median of 20% (IQR 17 to
24) poorly performing practices will be correctly identified and
most practices identified as poorly performing will be incorrectly
labelled. As the number of cases per practice rises, the accuracy of
prediction increases, but only slowly and incompletely: with 100
cases the probability of a poorly performing practice being
correctly identified is 44% (95% CI 40 to 47), and with 200 cases
it is 57% (54 to 59).
DISCUSSION
This is the first study to examine the effects of number of cases and
random case-mix on a publicly reported measure of GP practices’
performance in the use of USC pathways. The results indicate that
differences between practices, and apparent quality gradients, seen
within individual years are weakened when data are aggregated
over several years, suggesting that case-mix – different cancers with
different referral pathways – rather than actual clinical perfor-
mance accounts for much of the observed variation. The modelling
exercise suggests that at least 100 cancer cases per practice are
necessary before the probability is close to 50% that an observed
poorly performing practice is actually poorly performing. In terms
of an average-sized UK practice, it would take B4 years for the
number of cancer cases to accrue.
Our choice of two databases allows for both the extra detail
and duration of the northeast Scotland data set and the breadth
and generalisability of the NHS England data set. The fact that
broadly comparable results emerged strengthens our findings
Table 2. Annual data pooled from all practices to show the number of cancers detected by different pathways, number of USC
referrals and calculated annual detection and conversion rates
Cancers Referrals Rates (pooled practices)a
NHS Grampian Totalb Urgent (USC)c Urgent (other)d USC Detection Conversion
2006 1133 144 374 1079 0.127 0.133
2007 1186 167 357 1233 0.141 0.135
2008 1644 257 605 2097 0.156 0.123
2009 1667 643 464 3764 0.386 0.171
2010 1677 919 279 5143 0.548 0.179
2011 1783 975 320 5904 0.547 0.165
2012 1525 898 240 6058 0.589 0.148
Pooled 2006–2012 10615 4003 2639 25278 0.377 0.158
Pooled 2009–2012 6639 3435 1303 20774 0.516 0.165
Cancers Referrals Rates (pooled practices)a
NHS England Totale Urgent (USC) USC Detection Conversion
2010 199 317 89027 — 772840 0.447 0.115
2011 216 957 101260 — 907164 0.467 0.112
2012 229 173 109002 — 1007414 0.476 0.108
2013 235 634 114429 — 1120988 0.486 0.102
Pooled 2010–2013 881 080 413718 — 3808406 0.470 0.109
aThese rates are for all patients pooled across practices. They are thus slightly different from the mean practice rates shown in Table 1.
bIncludes data from all practice-years whether or not any cancer was referred via the USC (urgent suspected cancer) pathway.
cTotal number of cancers diagnosed after referral through the USC pathway.
dTotal number of cancers diagnosed after referral through other urgent pathway. Before 2006, this was the only pathway available in NHS Grampian Scotland. This analysis was only available at
practice level in Scotland.
eIncludes data only from practice-years in which full data were available (at least six cancer cases referred via the USC pathway).
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and adds credence to the belief that, in both data sets, the validity
and accuracy of cancer cases and referrals routes are acceptable.
Although the Scottish and English data sets were broadly similar,
they were not identical in their definitions, nor in the time of the
study in relation to introduction of specific cancer referral
pathways. Furthermore, the Scottish data were from one region
only, whereas the English data were from the whole country.
This precludes making comparisons between the data sets, and
instead the analysis focuses on within-data set comparisons
showing that similar findings appear in both. Both data sets had
limitations when it came to small numbers of cancer cases; in the
NHS England database, data from practices with less than six
USC referrals in 1 year were not available. We did not attempt to
impute these data. In addition, we did not attempt to address
other possible sources of practice variation, such as differences in
practice population rather than GP performance. Within the
Scottish data, there were some single-doctor practices with very
small list sizes, meaning that it was possible they would have a
year when no cancers were diagnosed. These null data were
excluded from the analysis since a meaningful detection
rate could not be calculated. However, as our data suggest
relatively modest variation in GP performance after adjusting for
random case-mix, any adjustment for practice characteristics
would be likely to further reduce the variation in intrinsic GP
performance.
We deliberately followed previously reported methods for
comparing single-year interpractice variation in the use of USC
referrals, as these measures are currently used in routine reporting
and public feedback (Meechan et al, 2012). This is despite the fact
that the method has an obvious limitation in that detection and
conversion rates are not a naturally complementary pair of
measures. One unexpected advantage of this pairing, however, is
that, unlike sensitivity and specificity, the relationship between
these two measures is not influenced by prevalence. Our finding
that the correlation between detection and conversion rates was
diminished (or reversed) by aggregating data over several years
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Figure 1. Scatter plots of detection rate vs conversion rate in different years, and aggregated across all available years, for each database. Lines
indicate linear regression (blue) and local polynomial regression (red). Northeast Scotland data points (N¼77) represent the practice size. A full
colour version of this figure is available at the British Journal of Cancer journal online.
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suggests that correlations based on small case numbers may be
largely spurious. In our modelling, we focused on the detection
rate, as this was the measure highlighted by media and politicians,
and also because this showed more year on year variation than the
conversion rate. It is not the only measure of diagnostic quality,
however, and further work may need to examine conversion rates
or other approaches such as imputing specificity.
Our modelling exercise was based on empirical data from
NHS England with the detection rate set according to this.
It was designed to use sample sizes that are representative of
routine practice. With an annual cancer incidence of around
4.3/1000 per annum, a small practice of 3000 patients can expect
only around 13 new cancer cases each year, and will need 8 years
to accumulate B100 cases. A medium-sized practice of
6000 patients (close to the UK average) will need 4 years. Only
a very large practice of around 24 000 patients is likely to record
100 cancer cases in a year. Even with 100 cases, our modelling
data indicate that the probability of a statistically outlying
practice being an intrinsically poor performer is still only
around 50%. At present, most practices identified as poorly
Table 4. Year to year correlation coefficients (95% confidence interval) for detection rate and conversion rate from GP practices
in England
Year to year correlation (95% confidence interval)a
Cancer Cases (per year) Years Practices Detection rate Conversion rate
N¼ 6–25 2010 vs 2011 1353 0.21 (0.15 to 0.26) 0.60 (0.56 to 0.63)
2011 vs 2012 1384 0.16 (0.11 to 0.22) 0.60 (0.56 to 0.64)
2012 vs 2013 1401 0.16 (0.11 to 0.21) 0.60 (0.56 to 0.64)
N¼ 26–50 2010 vs 2011 2416 0.28 (0.24 to 0.32) 0.48 (0.45 to 0.51)
2011 vs 2012 2471 0.20 (0.16 to 0.24) 0.52 (0.49 to 0.55)
2012 vs 2013 2443 0.22 (0.18 to 0.26) 0.53 (0.50 to 0.56)
N¼ 51–75 2010 vs 2011 875 0.29 (0.23 to 0.35) 0.55 (0.50 to 0.59)
2011 vs 2012 1008 0.22 (0.16 to 0.27) 0.50 (0.45 to 0.54)
2012 vs 2013 1108 0.21 (0.15 to 0.26) 0.52 (0.47 to 0.56)
N475 2010 vs 2011 250 0.33 (0.20 to 0.45) 0.58 (0.48 to 0.67)
2011 vs 2012 316 0.29 (0.19 to 0.39) 0.55 (0.46 to 0.62)
2012 vs 2013 394 0.35 (0.27 to 0.43) 0.63 (0.56 to 0.69)
All practices 2010 vs 2011 4894 0.26 (0.23 to 0.29) 0.53 (0.51 to 0.55)
2011 vs 2012 5179 0.20 (0.17 to 0.22) 0.54 (0.52 to 0.57)
2012 vs 2013 5346 0.21 (0.19 to 0.24) 0.55 (0.53 to 0.57)
All NHS Grampian 2006 vs 2007 38 0.26 (0.07 to 0.55) 0.3 ( 0.01 to 0.58)
2007 vs 2008 41 0.47 (0.2 to 0.66) 0.48 (0.21 to 0.68)
2008 vs 2009 62 0.25 (0.01 to 0.42) 0.47 (0.27 to 0.61)
2009 vs 2010 74 0.28 (0.09 to 0.44) 0.41 (0.16 to 0.61)
2010 vs 2011 72 0.01 (0.24 to 0.21) 0.05 ( 0.18 to 0.25)
2011 vs 2012 73 0.1 (0.11 to 0.33) 0.2 ( 0.01 to 0.39)
aSpearman rank correlation coefficient with bootstrapped 95% confidence intervals.
Table 3. Correlation coefficients (with 95% CIs) between the detection rate and conversion rate by year and aggregated over all
available years for each database
NHS Grampian NHS England
Year Coefficienta 95% CI P-value Coefficienta 95% CI P-value
2006 0.18  0.13 to 0.47 0.21 — — —
2007 0.28  0.05 to 0.48 0.05 — — —
2008 0.13  0.07 to 0.38 0.32 — — —
2009 0.28 0.08 to 0.53 0.01 — — —
2010 0.27 0.06 to 0.44 0.02 0.24 0.21 to 0.26 o0.001
2011 0.26 0.03 to 0.48 0.03 0.26 0.23 to 0.28 o0.001
2012 0.08  0.25 to 0.35 0.48 0.25 0.23 to 0.27 o0.001
2013 — — — 0.24 0.22 to 0.27 o0.001
Aggregated 2006–2012  0.22  0.41 to 0.08 0.08
2009–2012  0.16  0.34 to 0.01 0.12
2010–2013 0.12 0.09 to 0.14 o0.001
Abbreviation: CI¼ confidence interval.
aSpearman correlation coefficient with bootstrapped 95% confidence intervals.
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performing from annual data will be wrongly labelled, and most
poorly performing practices will not be detected.
Individual case presentations of cancer vary and this study
highlights the need to consider the number of cases and case-mix
variation in evaluating the performance of GP practices in their use
of USC referral. Simply reporting values for detection and
conversion rates on annual data, and considering all cancers
together, has a clear potential to mislead both practices and the
public. Allied concerns relating to case-mix and small volume
caseloads have recently been highlighted in reporting surgeon
performance (Walker et al, 2013).
On the basis of our findings, we propose that any reporting of
practice rates should now be limited to data aggregated over
several years and may need to consider each cancer site
separately. However, the substantial effect of random case-mix
on observed detection rates, even if GPs follow guidelines
exactly, means that alternative approaches are needed. We
suggest two ways to avoid the influence of case-mix on reported
performance. The first is to examine specifically whether cancer
cases were referred (or not) in accordance with national
guidelines. The second is to adopt a ‘confidential enquiry’
approach, employing a case review of designated delayed
diagnoses as ‘never events’ (de Wet et al, 2014). Although
both require more data, and more time to critically reflect
on it, they would be more transparent – and more likely to
lead to constructive changes in practice – than the current
crude approach to identification of supposedly poorly
performing practices. In the meantime, the widespread public
reporting of GP practice’s use of USC referral pathways based
on annual data may be misleading and should be interpreted
with caution until a more robust reporting methodology is in
place.
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Table 5. Results of the modelling of practice detection rates with both specified between-practice variation and random
case-mix variation
‘Poorly performing practices’
Model parametersa Observed data (detection rate)b Correctly identifiedc Total identifiedd
Cases s.d.e Min Max Median IQR Median IQR
Low variation (s.d.¼0.025)
25 0.1 0.16 0.8 18 14 – 19 87 80 – 93
50 0.07 0.24 0.72 19 16 – 21 77 70 – 82
75 0.06 0.27 0.69 24 21 – 27 87 79 – 92
100 0.06 0.29 0.66 28 24 – 29 87 78 – 94
150 0.05 0.32 0.64 30 27 – 34 89 84 – 95
200 0.04 0.34 0.63 35 33 – 38 91 86 – 96
Moderate variation (s.d.¼0.05)
25 0.11 0.12 0.84 20 17 – 24 58 53 – 64
50 0.09 0.2 0.76 31 28 – 35 77 69 – 89
75 0.08 0.23 0.73 39 36 – 43 85 78 – 94
100 0.07 0.25 0.71 44 40 – 47 89 83 – 95
150 0.06 0.27 0.69 52 48 – 55 91 88 – 95
200 0.06 0.28 0.68 57 54 – 59 94 89 – 97
High variation (s.d.¼0.075)
25 0.12 0.08 0.88 32 29 – 36 75 70 – 83
50 0.1 0.14 0.82 44 40 – 48 81 75 – 89
75 0.09 0.16 0.79 52 49 – 55 90 83 – 95
100 0.09 0.18 0.77 57 54 – 60 91 86 – 97
150 0.09 0.2 0.76 64 62 – 67 94 90 – 97
200 0.08 0.21 0.75 68 66 – 71 95 92 – 98
Abbreviations: IQR¼ interquartile range; Max¼maximum; Min¼minimum.
aFor each set of parameters, 200 sets of 1000 practices were modelled.
bValues for s.d., minimum and maximum represent median values for all runs of the simulation at each specification of practice variation and number of cancer cases.
cCorrectly identified poorly performing practices represents the median number (with interquartile range) of practices, which were in the lowest decile of detection rate before adjusting for
case-mix (N¼ 100) and which were also in the lowest decile of detection rate after introducing random case-mix variation.
dTotal identified poorly performing practices represents the median number (with interquartile range) of practices, which were in the lowest decile of detection rate after introducing random
case-mix variation.
eStandard deviation.
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